Skip to main content
OpenTrials
Completed

NCT Number: NCT02881060

The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes

Objective: Because many people with type 1 diabetes drink ethanol and because glucagon is used to treat mild hypoglycaemia, it is essential to determine whether ethanol will impair the effectiveness of glucagon to increase glucose, which may impair the effectiveness of the dual hormone treatment in preventing hypoglycaemia.

The purpose of this study is to determine, whether ethanol influences the glucose response to subcutaneous glucagon during mild hypoglycaemia.

The investigators hypothesize that prior evening ethanol consumption does not reduce the effect of a glucagon bolus to raise plasma glucose compared with no prior ethanol consumption.

The study aims:

1. To determine the late effects of ethanol on the efficacy of subcutaneous glucagon to restore plasma glucose after an episode of mild hypoglycemia. 2. To determine the late effects of ethanol on the counter-regulatory hormones and hypoglycaemia awareness during mild hypoglycaemia

A double-blinded placebo-controlled study will be conducted. Participants will serve as their own controls. Eligible participants will after an informed consent complete two study visits, one with and one without ethanol consumption, in a random order. On each study visit, participants are induced a insulin induced hypoglycemia, seven-eight hours after a meal with or without ethanol. Once plasma glucose is below 3.9 mmol/l, a subcutaneous injection of 100 mcg glucagon is administered. Two hours later a second bolus is administered.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hvidovre University Hospital

Hvidovre, 2650, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 70 years
  • T1D ≥ 3 year
  • BMI 20-28 kg/m2
  • CSII ≥ 1 year
  • Caucasian origin
  • Hypoglycaemia awareness (assessed by Gold, Clarke and Pedersen-Bjergaard methods)
  • Use of carbohydrate counting and the insulin pump bolus calculator for all meals
  • Ethanol exposure once within 1 year consisting of at least 4 drinks (1 drink contains 12 gram ethanol) within four hours

Exclusion criteria

  • Allergy or intolerance to lactose or Glucagen®(Novo Nordisk, Bagsværd, DK)
  • Allergy for ethanol or any food ingredients that will be used in the study.
  • Impaired renal function (eGFR < 60 ml/min/1.73m2)
  • Liver disease with ALAT > 2.5 times the upper limit of the reference interval
  • Gastropareses (beat-beat variation < 10 beats per min and/or orthostatic systolic blood pressure > 20 mmHg)
  • Insomnia, sleep apnoea or any troubles with sleeping that according to the investigator's assessment makes the individual unsuitable for study participation.
  • Aldehyde dehydrogenase deficiency as determined by a screening questionnaire
  • Unable to refrain from the consumption of ethanol at least 24 hours prior to study start
  • History of drinking problems or alcoholism, regardless of whether active or in remission.
  • Use of benzodiazepines or barbiturates or opiates or other central nervous system depressant drugs that could act synergistically with ethanol to lower the level of consciousness
  • History of drug abuse
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject.
  • Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  • Use of medications that are known to cause QT interval prolongation
  • Presence of pheochromocytoma
  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the individual unsuitable for study participation
  • Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
  • Females who have different basal insulin pattern depending on their menstrual cycle.
  • Inability to understand the individual information and to give informed consent.

Treatment and study plan

Alcohol

Dietary Supplement

Other names: Cocktail

Placebo

Dietary Supplement

Other names: Mocktail

Primary outcomes

  1. Increase in plasma glucose

    Time frame: 0-120 min after the first glucagon injection

    The primary endpoint is difference in increase in plasma glucose value after the first injection of 100 µg s.c. glucagon on study nights with ethanol vs. study nights without ethanol consumption.

Secondary outcomes

  1. Peak plasma glucose

    Time frame: 0-240 min after the first glucagon injection

    Maximal plasma glucose after the first and second glucagon injection

  2. Increase in plasma glucose

    Time frame: 0-120 min after the second glucagon injection

    Increase in plasma glucose caused by the second glucagon injection.

  3. Total AUC(0-120)

    Time frame: 0-240 min after the first glucagon injection

    Total area under the glucose curve from 0-120 minutes after each glucagon injection

  4. PI-AUC(0-120)

    Time frame: 0-240 min after the first glucagon injection

    positive incremental area under the glucose curve from 0-120 minutes after each glucagon injection

  5. Tmax

    Time frame: 0-240 min after the first glucagon injection

    Time-to-peak glucose value after each glucagon injection glucagon injection

  6. Time above 4.0mM

    Time frame: 0-240 min after the first glucagon injection

    Duration of glucose above 4.0 mmol/l after first and second glucagon injection

  7. Time above baseline

    Time frame: 0-240 min after the first glucagon injection

    Duration of glucose above baseline after first and second glucagon injection

  8. Rescue rates

    Time frame: 0-240 min after the first glucagon injection

    Numbers of first and second glucagon injections that raises PG > 4.9 mmol/l

  9. Hyperglycemia rates

    Time frame: 0-240 min after the first glucagon injection

    Number of first and second glucagon injections that raises PG > 7.1 mmol/l

  10. Changes in plasma ketone bodies, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  11. Changes in plasma ketone bodies, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  12. Changes in plasma glucagon, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  13. Changes in plasma glucagon, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  14. Changes in insulin, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  15. Changes in insulin, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  16. Changes in growth hormones, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  17. Changes in growth hormones, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  18. Changes in serum corticole, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  19. Changes in serum corticole, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  20. Changes in plasma ethanol, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  21. Changes in plasma ethanol, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  22. Changes in free fatty acids, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  23. Changes in free fatty acids, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  24. Changes in triglycerides, measured as area under the curve

    Time frame: 0-240 min after the first glucagon injection

  25. Changes in triglycerides, measured as incremental peak

    Time frame: 0-240 min after the first glucagon injection

  26. Average in blood pressure

    Time frame: 0-240 min after the first glucagon injection

  27. Average heart rate

    Time frame: 0-240 min after the first glucagon injection

  28. Intensity of hypoglycemia

    Time frame: 0-240 min after the first glucagon injection

    Average changes in Edinburgh Hypoglycaemia Scale over time during insulin and glucagon phase

  29. Cognitive impairment

    Time frame: 0-240 min after the first glucagon injection

    Average scores in cognitive test 30 min before each glucagon injection.

  30. Side effects

    Time frame: 0-240 min after the first glucagon injection

    Average visual analogue scale score from 0-180 min for nausea and headache after glucagon injection

  31. Incidence of vomiting

    Time frame: 0-240 min after the first glucagon injection

    Incidence of vomiting after 0-4 hours after each glucagon injection.

  32. Meal induced glucose excursion

    Time frame: 0-3 hours after meal

    Total and incremental area under the glucose curve from 0-120 and 0-240 min after eating the mixed meal

  33. Meal induced hormonal changes

    Time frame: 0-3 hours after meal

    Total and incremental area under the glucose curve from 0-120 and 0-240 min after eating the mixed meal

  34. Nocturnal changes in plasma glucose

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  35. Nocturnal changes in corticol

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  36. Nocturnal changes in growth hormone

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  37. Nocturnal changes in ketones

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  38. Nocturnal changes in ethanol

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  39. Nocturnal changes in glucagon

    Time frame: 0-6 hours after start of sleep

    Area under the curve during sleep

  40. Difference between the first second glucagon injection and between both study visits in peak change plasma glucose

    Time frame: 0-240 min after the first glucagon injection

  41. Difference between glucagon injections on both study visits in positive incremental area under the glucose curve from 0-120 minutes

    Time frame: 0-240 min after the first glucagon injection

  42. Difference between glucagon injections on both study visits in total area under the glucose curve from 0-120 minutes

    Time frame: 0-240 min after the first glucagon injection

  43. Difference between glucagon injections on both study visits in time-to-peak glucose value

    Time frame: 0-240 min after the first glucagon injection

  44. Difference between glucagon injections on both study visits in duration of glucose above 4.0 mmol/l after first and second glucagon injection

    Time frame: 0-240 min after the first glucagon injection

  45. Difference between glucagon injections on both study visits in duration of glucose above baseline after first and second glucagon injection

    Time frame: 0-240 min after the first glucagon injection

  46. Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Mean absolute relative difference (MARD) values of glucose sensors compared with YSI from 7 PM- 8 AM.

    Time frame: 0-10 hours after meal

    Intentions to treat analysis

  47. Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Precision absolute relative difference (PARD) 120 min before and 120 after each glucagon injection.

    Time frame: 0-10 hours after meal

    Intentions to treat analysis

  48. Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - MARD values between glucose sensors 0-120 minutes after each glucagon injection.

    Time frame: 0-10 hours after meal

    Intentions to treat analysis

  49. Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in range (glucose sensor value =4.0-10.0mmol/l)

    Time frame: 0-2 days after the first glucagon injection

    Intentions to treat analysis

  50. Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hypoglycaemia (glucose sensor value < 4.0 mmol/l)

    Time frame: 0-2 days after the first glucagon injection

    Intentions to treat analysis

  51. Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hyperglycaemia (glucose sensor value >10.0mmol/l)

    Time frame: 0-2 days after the first glucagon injection

    Intentions to treat analysis

  52. Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)

    Time frame: 0-2 days after the first glucagon injection

    Intentions to treat analysis

  53. Difference in glucose sensor data between the study period with and without alcohol - Clarke- Error Grid analysis for both sensors compared with YSI during study visit

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

  54. Difference in glucose sensor data between the study period with and without alcohol - PARD values from day 1-7

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

  55. Difference in glucose sensor data between the study period with and without alcohol - PARD values <4.0 mmol/L from day 1-7

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

  56. Difference in glucose sensor data between the study period with and without alcohol - PARD values 4.0-10.0 mmol/L from day 1-7

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

  57. Difference in glucose sensor data between the study period with and without alcohol PARD values >10.0 mmol/L from day 1-7

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

  58. Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)

    Time frame: -2 to 4 days after study visits

    Intentions to treat analysis

Sponsors and collaborators

Lead sponsor

Hvidovre University Hospital

Other

Collaborators

  • Danish Diabetes Academy
  • University of Copenhagen

Registry information

Acronym: ALCO1

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Aug 26, 2016
Registry last updated
Jul 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.